Participating Faculty: Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus

This supplement to The American Journal of Managed Care describes the use of an economic model to compare the cost efficiency of treating type 2 diabetes mellitus with canagliflozin 300 mg versus sitagliptin 100 mg. The modeled clinical and economic outcomes analyses provide information to managed care decision makers in the absence of real-world effectiveness and cost outcomes data. The analyses focused on the achievement of short-term goals that are consistent with recognized diabetes quality metrics, and the results may be useful in aligning reimbursement and best clinical practices.This supplement was sponsored by Janssen Pharmaceuticals, Inc.

This analysis was funded, in part, by Janssen Scientific Affairs, LLC, and was based on data from a study supported by Janssen Research & Development, LLC. Editorial support was provided by Cherie Koch, PhD, of MedErgy, and was funded by Janssen Scientific Affairs, LLC.

Faculty

Marc F. Botteman, MSc, MA

Partner

Pharmerit International

Bethesda, Maryland

Varun U. Ektare, BPharm, MPH

Lead Outcomes Research Analyst

Pharmerit International

Bethesda, Maryland

Janice M. S. Lopez, PharmD, MPH

Associate Director

Health Economics and Outcomes Research

Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Raritan, New Jersey

Silas C. Martin, MS

Director

Health Economics and Outcomes Research

Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Raritan, New Jersey

Dipen A. Patel, BPharm, PhD

Director

HEOR

Pharmerit International

Bethesda, Maryland

Marcia F. T. Rupnow, PhD

Senior Director

Health Economics and Outcomes Research

Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Raritan, New Jersey

Faculty Disclosures

These faculty report relationships with the following organizations:

Marc F. Botteman, MSc, MA

Stock ownership: Pharmerit International

Janice M. S. Lopez, PharmD, MPH

Employment: Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Stock/shareholder: Johnson & Johnson

Silas C. Martin, MS

Employment: Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Stock ownership: Johnson & Johnson

Marcia F. T. Rupnow, PhD

Employment and meeting/conference attendance: Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Stock ownership: Johnson & Johnson

Varun U. Ektare, BPharm, MPH; and Dipen A. Patel, BPharm, PhD, report no relationships or financial interests with any entity that would pose a conflict of interest with the subject matter of this supplement.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Download PDF: Participating Faculty: Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus